AbbVie and Amgen lock horns in the latest squabble over biosimilars

(By Ed Silverman for STAT)

In the latest contest over biosimilars, AbbVie has filed a patent infringement lawsuit against Amgen, an erstwhile rival in the market for hard-to-make treatments for rheumatoid arthritis. And the move highlights a strategy designed to indefinitely delay the arrival of a lower-cost biosimilar indefinitely while the litigation plays out. Continue reading article here…..

 

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.